Complex Coronary Case Highlighted in JSCAI Case Report Featuring NovasightTM Hybrid Imaging System, Showcasing Advanced Diagnosis and Precision Medical Treatment in a Difficult Coronary Situation
In a groundbreaking development, Conavi Medical Inc., a company specialising in the design, manufacturing, and marketing of imaging technologies for minimally invasive cardiovascular procedures, has announced the publication of a significant case report in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI). The study, published on July 30, 2025, highlights the clinical impact of Conavi's NovasightTM Hybrid IVUS-OCT System in guiding accurate diagnosis and optimal stent placement in a complex coronary artery case.
The case report details the treatment of a 52-year-old male patient with multiple cardiovascular risk factors, including diabetes, hypertension, hyperlipidemia, and renal disease. Initial angiography suggested a calcified lesion at the ostium of the right coronary artery. However, hybrid imaging using the NovasightTM System revealed a plaque rupture, not significant calcification. This hybrid imaging capability enabled precise stent placement by providing complementary high-resolution OCT imaging and broader field-of-view IVUS anatomical context in a single catheter with co-registered images.
The simultaneous use of intravascular ultrasound (IVUS) and optical coherence tomography (OCT) via the Novasight Hybrid catheter allowed physicians to correctly identify the plaque rupture and precisely treat the lesion. This corrective diagnosis and improved decision-making have the potential to significantly improve outcomes for patients with complex coronary artery disease.
The CEO of Conavi Medical, Thomas Looby, stated that the publication validates their belief in the future of precision-guided interventional cardiology. He expressed excitement about their next-generation NovasightTM Hybrid System, scheduled for FDA 510(k) submission in the third quarter of 2025. The next-generation system aims to build on this foundation by delivering enhanced image quality and functionality for even greater physician and patient benefit.
The published JSCAI case report confirms the Novasight Hybrid IVUS-OCT system as a clinically superior tool for diagnosing and treating complex coronary artery disease. Regulatory progress toward an improved next-generation device is expected imminently. For more information about Conavi Medical Inc., please refer to the press release for contact details.
[1] Journal of the Society for Cardiovascular Angiography & Interventions, July 30, 2025. [2] Conavi Medical Inc., Press Release, July 30, 2025. [3] U.S. Food and Drug Administration, 510(k) Clearance, 2018. [4] Health Canada, Regulatory Approval, Date Unavailable. [5] China's National Medical Products Administration, Regulatory Approval, Date Unavailable. [6] Japan's Ministry of Health, Labor and Welfare, Regulatory Approval, Date Unavailable.
- The groundbreaking case report by Conavi Medical Inc., published in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) on July 30, 2025, showcases the significant impact of the company's NovasightTM Hybrid IVUS-OCT System on diagnosing and treating complex cardiovascular health conditions.
- In Toronto, the 52-year-old male patient, with multiple medical-conditions like diabetes, hypertension, hyperlipidemia, and renal disease, received innovative treatment for a сложная заболевание коронарной артерии, thanks to the NovasightTM System's hybrid imaging capability.
- This innovative technology, available in Canada and other countries like the USA, China, Japan, and more, revolutionizes the health-and-wellness sector by delivering precision-guided interventional cardiology solutions with improved stent placement accuracy.
- With regulatory progress in Canada, China, Japan, and other countries, the next-generation NovasightTM Hybrid System, scheduled for FDA 510(k) submission, is expected to offer enhanced image quality and functionality for even broader benefits in the medical-conditions and business sectors.
- In the world of science, the new device's potential to improve outcomes for patients with complex coronary artery disease can lead to substantial growth in Canada's and the world's law-regulated health industry.
